fenofibrate has been researched along with Diabetic Angiopathies in 43 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 9.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 9.14 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Burgess, DC; Davis, TM; Hunt, D; Keech, AC; Kesäniemi, YA; Laakso, M; Lehto, S; Li, L; Mann, S; Sy, RW; Williamson, E; Zannino, D; Zhang, J, 2010) |
| "The Diabetes Atherosclerosis Intervention Study (DAIS) examined the effects of fenofibrate or placebo on the progression of coronary artery disease (CAD) in 418 type 2 diabetic subjects with dyslipidemia." | 9.11 | Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. ( Frohlich, J; Genest, J; Steiner, G, 2004) |
| "Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α." | 6.47 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. ( Keating, GM, 2011) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 5.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 5.14 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Burgess, DC; Davis, TM; Hunt, D; Keech, AC; Kesäniemi, YA; Laakso, M; Lehto, S; Li, L; Mann, S; Sy, RW; Williamson, E; Zannino, D; Zhang, J, 2010) |
| "The Diabetes Atherosclerosis Intervention Study (DAIS) examined the effects of fenofibrate or placebo on the progression of coronary artery disease (CAD) in 418 type 2 diabetic subjects with dyslipidemia." | 5.11 | Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. ( Frohlich, J; Genest, J; Steiner, G, 2004) |
| " Evidence from the Fenofibrate Intervention and Event Lowering in Diabetes study suggests that fenofibrate reduces the risk of long-term macrovascular and microvascular type 2 diabetic complications, especially in patients demonstrating features of the metabolic syndrome." | 4.85 | Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. ( Toth, PP, 2009) |
| "Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates 2-4 times higher than patients without diabetes but with similar demographic characteristics." | 3.82 | Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. ( Buse, JB; Byington, RP; Cushman, WC; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Margolis, KL; Probstfield, JL; Simons-Morton, DG, 2007) |
| "In adults with type 2 diabetes and known or suspected atherosclerosis, arterial smooth muscle-dependent dilatation was shown to be significantly impaired in cigarette smokers and those with elevated urinary albumin levels." | 2.79 | Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Marwick, TH; Meredith, IT; Skilton, MR; Veillard, AS; Watts, GF, 2014) |
| "Most patients with type 2 diabetes mellitus develop cardiovascular disease (CVD), with substantial loss of life expectancy." | 2.73 | Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. ( Bigger, JT; Buse, JB; Byington, RP; Cooper, LS; Cushman, WC; Friedewald, WT; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Margolis, KL; Probstfield, JL; Simons-Morton, DG; Sullivan, MD, 2007) |
| "A total of 418 subjects with type 2 diabetes were randomly assigned to 200 mg micronized fenofibrate daily or placebo." | 2.71 | Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Aubin, F; Foucher, C; Hamsten, A; Rattier, S; Steiner, G; Taskinen, MR; Vakkilainen, J, 2003) |
| "Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis." | 2.71 | Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. ( Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB, 2003) |
| "The incidence of coronary artery disease is greatly increased in those with diabetes mellitus." | 2.68 | The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. ( Steiner, G, 1996) |
| "Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α." | 2.47 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. ( Keating, GM, 2011) |
| "Patients with type 2 diabetes or metabolic syndrome remain at high residual risk of cardiovascular events even after intensive statin therapy." | 2.45 | Combination statin-fibrate therapy: safety aspects. ( Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M, 2009) |
| "Fenofibrate is a reasonable second-line therapy for dyslipidaemia in diabetes and safe in combination therapy." | 2.43 | FIELDS of dreams, fields of tears: a perspective on the fibrate trials. ( Wierzbicki, AS, 2006) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Fenofibrate is an agonist of peroxisome proliferator-activated receptor α and can reduce the incidence of cardiovascular events in diabetic patients." | 1.51 | Fenofibrate improves vascular endothelial function in diabetic mice. ( An, D; Fu, J; Huang, F; Li, Y; Xin, R; Zhu, Q, 2019) |
| " It seems that fenofibrate enhances angiogenesis in hind limb ischemia possibly through increasing of NO bioavailability and can be considered for treatment of diabetic peripheral vascular diseases in future human studies." | 1.38 | Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats. ( Khazaei, M; Rashidi, B; Salehi, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 26 (60.47) | 29.6817 |
| 2010's | 13 (30.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morieri, ML | 1 |
| Gao, H | 1 |
| Pigeyre, M | 1 |
| Shah, HS | 1 |
| Sjaarda, J | 1 |
| Mendonca, C | 1 |
| Hastings, T | 1 |
| Buranasupkajorn, P | 1 |
| Motsinger-Reif, AA | 1 |
| Rotroff, DM | 1 |
| Sigal, RJ | 1 |
| Marcovina, SM | 1 |
| Kraft, P | 1 |
| Buse, JB | 3 |
| Wagner, MJ | 1 |
| Gerstein, HC | 3 |
| Mychaleckyj, JC | 1 |
| Parè, G | 1 |
| Doria, A | 1 |
| Xin, R | 1 |
| An, D | 1 |
| Li, Y | 1 |
| Fu, J | 1 |
| Huang, F | 1 |
| Zhu, Q | 1 |
| Kitajima, S | 1 |
| Furuichi, K | 1 |
| Wada, T | 1 |
| Linz, PE | 2 |
| Lovato, LC | 2 |
| Byington, RP | 3 |
| O'Connor, PJ | 2 |
| Leiter, LA | 2 |
| Weiss, D | 2 |
| Force, RW | 1 |
| Crouse, JR | 2 |
| Ismail-Beigi, F | 1 |
| Simmons, DL | 1 |
| Papademetriou, V | 1 |
| Ginsberg, HN | 4 |
| Elam, MB | 2 |
| Harmer, JA | 1 |
| Keech, AC | 3 |
| Veillard, AS | 1 |
| Skilton, MR | 1 |
| Marwick, TH | 1 |
| Watts, GF | 4 |
| Meredith, IT | 1 |
| Celermajer, DS | 1 |
| Simó, R | 1 |
| Simó-Servat, O | 1 |
| Hernández, C | 1 |
| Williams, KH | 1 |
| Sullivan, DR | 1 |
| Nicholson, GC | 1 |
| George, J | 1 |
| Jenkins, AJ | 2 |
| Januszewski, AS | 1 |
| Gebski, VJ | 1 |
| Manning, P | 1 |
| Tan, YM | 1 |
| Donoghoe, MW | 1 |
| Ehnholm, C | 1 |
| Young, S | 1 |
| O'Brien, R | 1 |
| Buizen, L | 1 |
| Twigg, SM | 1 |
| Franssen, R | 1 |
| Vergeer, M | 1 |
| Stroes, ES | 1 |
| Kastelein, JJ | 1 |
| Ansquer, JC | 3 |
| Foucher, C | 2 |
| Aubonnet, P | 1 |
| Le Malicot, K | 1 |
| Zimmet, P | 1 |
| Pruski, M | 1 |
| Krysiak, R | 1 |
| Okopien, B | 1 |
| Toth, PP | 1 |
| Steiner, G | 7 |
| Burgess, DC | 1 |
| Hunt, D | 1 |
| Li, L | 1 |
| Zannino, D | 1 |
| Williamson, E | 1 |
| Davis, TM | 2 |
| Laakso, M | 1 |
| Kesäniemi, YA | 2 |
| Zhang, J | 1 |
| Sy, RW | 1 |
| Lehto, S | 1 |
| Mann, S | 1 |
| Chan, DC | 2 |
| Hamilton, SJ | 1 |
| Rye, KA | 1 |
| Chew, GT | 2 |
| Lambert, G | 1 |
| Keating, GM | 1 |
| Rosenblit, PD | 1 |
| Wong, AT | 1 |
| Yamashita, S | 1 |
| Salehi, E | 1 |
| Khazaei, M | 1 |
| Rashidi, B | 1 |
| Leinonen, ES | 1 |
| Salonen, JT | 1 |
| Salonen, RM | 1 |
| Koistinen, RA | 1 |
| Leinonen, PJ | 1 |
| Sarna, SS | 1 |
| Taskinen, MR | 4 |
| Yoshizawa, M | 1 |
| Takamura, T | 1 |
| Kobayashi, K | 1 |
| Vakkilainen, J | 2 |
| Aubin, F | 1 |
| Rattier, S | 1 |
| Hamsten, A | 1 |
| Talmud, PJ | 1 |
| Martin, S | 1 |
| Flavell, DM | 1 |
| Whitehouse, DB | 1 |
| Nagl, S | 1 |
| Jackson, R | 1 |
| Frick, MH | 1 |
| Nieminen, MS | 1 |
| Pasternack, A | 1 |
| Humphries, SE | 1 |
| Syvänne, M | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 1 |
| Genest, J | 1 |
| Frohlich, J | 1 |
| Wu, KK | 1 |
| Wu, TJ | 1 |
| Chin, J | 1 |
| Mitnaul, LJ | 1 |
| Hernandez, M | 1 |
| Cai, TQ | 1 |
| Ren, N | 1 |
| Waters, MG | 1 |
| Wright, SD | 1 |
| Cheng, K | 1 |
| Bailey, CJ | 1 |
| Wierzbicki, AS | 1 |
| Rees, A | 1 |
| Conaway, DG | 1 |
| O'Keefe, JH | 1 |
| Otsuki, M | 1 |
| Goya, K | 1 |
| Kasayama, S | 1 |
| Bigger, JT | 1 |
| Cooper, LS | 1 |
| Cushman, WC | 2 |
| Friedewald, WT | 1 |
| Genuth, S | 2 |
| Goff, DC | 2 |
| Grimm, RH | 1 |
| Margolis, KL | 2 |
| Probstfield, JL | 2 |
| Simons-Morton, DG | 2 |
| Sullivan, MD | 1 |
| Bonds, DE | 1 |
| Lipkin, E | 1 |
| Fleg, JL | 1 |
| Zambon, A | 1 |
| Cusi, K | 1 |
| Brinton, EA | 1 |
| Stuckey, BG | 1 |
| Beilin, LJ | 1 |
| Thompson, PL | 1 |
| Burke, V | 1 |
| Currie, PJ | 1 |
| McLaughlin, PR | 1 |
| Gladstone, P | 1 |
| Stewart, D | 1 |
| Hosking, JD | 1 |
| Perttunen-Nio, H | 1 |
| Hajós, P | 1 |
| Tornyossi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk Peopl[NCT00069784] | Phase 3 | 12,537 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation (MAGNETIC-PPARA)[NCT05542147] | 200 participants (Anticipated) | Interventional | 2022-07-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2). (NCT00069784)
Timeframe: from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years)
| Intervention | percentage of patients (Number) |
|---|---|
| Insulin Glargine | 24.7 |
| Standard Care | 31.2 |
Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee. (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 559 |
| Standard Care | 561 |
Number of deaths due to any cause (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 951 |
| Standard Care | 965 |
"The composite outcome used to analyze microvascular disease progression contained components of clinical events:~the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);~the development of blindness due to DR;~the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:~doubling of serum creatinine; or~progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine])." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: vitrectomy | Endpoint's composition: laser therapy for DR | Endpoint's composition: dialysis | Endpoint's composition: renal transplant | Endpoint's composition: serum creatinine doubled | Endpoint's composition: death due to renal failure | Endpoint's composition: albuminuria progression | |
| Insulin Glargine | 1323 | 24 | 57 | 18 | 0 | 82 | 4 | 1153 |
| Standard Care | 1363 | 25 | 67 | 28 | 0 | 88 | 3 | 1171 |
"Number of participants with a first occurrence of one of the above events.~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | |
| Insulin Glargine | 1041 | 484 | 297 | 261 |
| Standard Care | 1013 | 476 | 282 | 256 |
"Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | Endpoint's composition: revascularization | Endpoint's composition: hospitalization for HF | |
| Insulin Glargine | 1792 | 350 | 257 | 231 | 763 | 249 |
| Standard Care | 1727 | 339 | 238 | 227 | 717 | 259 |
"Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant's diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.~Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:~the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or~the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration." (NCT00069784)
Timeframe: on-treatment period (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Patients with hypoglycemia events | Patients with non-severe hypoglycemia | Patients with confirmed non-severe hypoglycemia | Patients with severe hypoglycemia | |
| Insulin Glargine | 3597 | 3533 | 2581 | 352 |
| Standard Care | 1624 | 1582 | 904 | 113 |
16 reviews available for fenofibrate and Diabetic Angiopathies
| Article | Year |
|---|---|
[Impact of dyslipidemia on the onset and progression of diabetic complications].
Topics: Cerebrovascular Disorders; Coronary Disease; Diabetic Angiopathies; Diabetic Nephropathies; Dyslipid | 2013 |
Is fenofibrate a reasonable treatment for diabetic microvascular disease?
Topics: Diabetic Angiopathies; Fenofibrate; Humans; Microvessels; Treatment Outcome | 2015 |
Combination statin-fibrate therapy: safety aspects.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2009 |
Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2009 |
Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.
Topics: Community Health Services; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combinati | 2009 |
How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Topics: Albuminuria; Amputation, Surgical; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Fenofibrate; Humans; Hypol | 2011 |
Do persons with diabetes benefit from combination statin and fibrate therapy?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Female; | 2012 |
[Soluble VCAM-1].
Topics: Biomarkers; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; | 2002 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell | 2006 |
FIELD study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2006 |
Frequency of undiagnosed and untreated diabetes mellitus in patients with acute coronary syndromes.
Topics: Angina, Unstable; Blood Glucose; Comorbidity; Diabetes Mellitus; Diabetic Angiopathies; Fenofibrate; | 2006 |
Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Topics: Antihypertensive Agents; Atherosclerosis; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; | 2005 |
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofib | 2007 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D | 2008 |
20 trials available for fenofibrate and Diabetic Angiopathies
| Article | Year |
|---|---|
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 2014 |
Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy.
Topics: Aged; Albuminuria; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, V | 2014 |
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Alanine Transaminase; Australia; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type | 2016 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Di | 2009 |
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Electrocardiography; Female; Fenofibrate; Fo | 2010 |
Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2010 |
Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein B-48; Apolipoprotein C-III; Brachial Artery; Chole | 2012 |
Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.
Topics: Aged; Carotid Arteries; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; | 2002 |
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angi | 2003 |
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino A | 2003 |
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2004 |
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; Glycated Hem | 2007 |
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofib | 2007 |
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Sched | 2007 |
Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabe | 2008 |
The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.
Topics: Adult; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; | 1996 |
Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis.
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angi | 1998 |
Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Diseas | 1999 |
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; H | 2002 |
8 other studies available for fenofibrate and Diabetic Angiopathies
| Article | Year |
|---|---|
Fenofibrate improves vascular endothelial function in diabetic mice.
Topics: Animals; Aorta, Thoracic; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelial Cells; | 2019 |
Preventing diabetic complications: a primary care perspective.
Topics: Cost of Illness; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neu | 2009 |
Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats.
Topics: Animals; Diabetic Angiopathies; Fenofibrate; Hindlimb; Hypolipidemic Agents; Ischemia; Male; Neovasc | 2012 |
[Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].
Topics: Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofi | 2002 |
Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiop | 2005 |
Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
Topics: Age Factors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; | 2006 |
The role of fenofibrate in clinical practice.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2007 |
Effect of lipanthyl in hyperlipoproteinaemic diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fe | 1989 |